Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment New Haven, CT, April 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented an evaluation of Health-Related Quality-of-Life (HRQL) in acute bacterial skin and skin structure infection...

Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...

Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today provided an update on the Company's innovative ESKAPE Pathogen Program. The ESKAPE Pathogen Program leverages Melinta's...

Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that...